Clinical trials: Depressive Disorder NOS
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158533
- Testing
- High Dose ALKS 5461, Low Dose ALKS 5461
- Where
- 49 sites in United States, Australia and 1 more
- Volunteers
- 385 people
- Sponsor
- Alkermes, Inc.
Bipolar Disorder, Major Depression
Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI
The purpose of the study is to find out what parts of the brain have increased or decreased activity and connectivity in individuals who have bipolar disorder, major depression, or no history of mood disorder.
- Trial name
- NCT01811147
- Testing
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Major Depression
Increasing Use of Mental Health Services
The purpose of this study is to test the effectiveness of Open Door (previously known as the Treatment Initiation Program [TIP]), a brief psychosocial intervention to address the psychological barriers to care and improve the use…
- Trial name
- OpenDoor (NCT00605358)
- Testing
- Open Door intervention
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to explore patterns of Brain Network Activation (BNA) changes from baseline to endpoint on 1) efficacy of core symptoms of Major Depressive Disorder (MDD) and 2) improvement of cognitive dysfunction…
- Trial name
- NCT02749721
- Testing
- vortioxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Rush University Medical Center
Major Depressive Disorder
A Study of the Effect of LY2216684 on Lorazepam
The purpose of this study is to determine how much lorazepam gets into the blood and how long it takes the body to get rid of it when given together with LY2216684.
- Trial name
- NCT01275144
- Testing
- LY2216684, Lorazepam
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Depression, Epinephrine, and Platelet Function
Men and women who have suffered sexual and/or physical abuse before the age of 12 are at increased risk for anxiety and mood disorders, other serious psychiatric disorders, and likely medical illnesses.
- Trial name
- NCT00166114
- Testing
- Escitalopram, Desipramine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Emory University
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.
- Trial name
- VLZ-MD-22 (NCT02372799)
- Testing
- Vilazodone, Fluoxetine
- Where
- 60 sites in United States, Canada
- Volunteers
- 473 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder (MDD)
The Effects of Dopamine on Reward Processing
The purpose of this study is to evaluate the effects of a single low dose of the D2/D3 antagonist amisulpride on reward processing.
- Trial name
- NCT01253421
- Testing
- amisulpride
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ
On 6 Feb 2014, Pristiq was approved for the treatment of Major Depressive Disorder(MDD) in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS for 600 patients by 5 Feb 2020.
- Trial name
- PMS (NCT02548949)
- Where
- 22 sites in South Korea
- Volunteers
- 700 people
- Sponsor
- Pfizer
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression
This study will compare the effect of three transcranial photobiomodulation (t-PBM) doses (high, middle, and low irradiance) to sham t-PBM on PFC CBF as assessed with fMRI (BOLD) in this multi-center, phase I, double-blinded…
- Trial name
- TRIADE (NCT04366258)
- Testing
- Transcranial Photobiomodulator
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- NYU Langone Health
Obsessive-Compulsive Disorder, Generalized Anxiety Disorder
Improving Attentional and Cognitive Control in the Psychological Treatment of Intrusive Thoughts
The investigators are conducting this study to learn more about the cognitive and attentional processes among individuals with three types of repetitive negative thinking (RNT): mental rituals (as seen in obsessive compulsive…
- Conditions
- Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Major Depressive Disorder
- Trial name
- NCT04225624
- Testing
- Emotion Regulation Therapy - Attention Regulation (AR-ERT), Supportive Psychotherapy (SPT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Safety of REL-1017 for Major Depressive Disorder
This was a 1-year, multicenter, open-label, long-term study to assess the safety of REL-1017 once daily (QD) as monotherapy or as adjunctive treatment of Major Depressive Disorder.
- Trial name
- RELIANCE-OLS (NCT04855760)
- Testing
- REL-1017
- Where
- 9 sites in United States
- Volunteers
- 627 people
- Sponsor
- Relmada Therapeutics, Inc.
Depressive Disorder, Anhedonia
Study to Treat Major Depressive Disorder With a New Medication
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga…
- Trial name
- NCT03043560
- Testing
- Ezogabine
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- James Murrough
Major Depressive Disorder
Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder
The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition.
- Trial name
- NCT00529789
- Testing
- duloxetine
- Where
- 22 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02218008
- Testing
- ALKS 5461
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 407 people
- Sponsor
- Alkermes, Inc.
Bipolar Disorder, Depression
A Trial of SAMe for Treatment-Resistant Bipolar Depression
S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants.
- Conditions
- Bipolar Disorder, Depression, Bipolar Depression
- Trial name
- NCT00762268
- Testing
- SAMe
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mclean Hospital
Major Depression
Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment
The antidepressant medications are among the most commonly prescribed pharmacological agents in patients with mood and anxiety disorder.
- Trial name
- NCT03927950
- Testing
- escitalopram, bupropion
- Where
- Estonia
- Volunteers
- 135 people
- Sponsor
- University of Tartu
Major Depressive Disorder
A Novel Cognitive Remediation Intervention Targeting Poor Decision-making and Depression in Veterans at High Risk for Suicide: A Safe, Telehealth Approach During the COVID-19 Pandemic
Despite large-scale, nationwide efforts to better address suicidal behavior in Veterans at high risk, the development of interventions that target some of the key risk factors associated with suicide remains limited.
- Trial name
- CogRemVet (NCT04952532)
- Testing
- Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Depression
Emotional and Cognitive Control in Late-Onset Depression
This study may help identify how abnormalities in brain systems that control the ability to ignore irrelevant information may contribute to the development of depression in older adults.
- Trial name
- NCT01728194
- Testing
- Escitalopram, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University